John D. Cravero is an associate with McDonnell Boehnen Hulbert & Berghoff LLP. Dr. Cravero is primarily engaged in the prosecution of patents in the areas of biotechnology and pharmaceuticals and diagnostics. His practice further includes client counseling and preparation of invalidity, patentability, and non-infringement opinions. His technical expertise includes molecular and cellular biology, biochemistry, microbiology, and animal models, and material science.
Prior to joining the firm, Dr. Cravero served as a patent attorney for the United States Department of Energy wherein he conducted patentability opinions, drafted patent applications, and prepared responses to Office Actions issued by the U.S. Patent and Trademark Office in the biotechnology, chemical, material science, and renewable energy fields, including applications directed to technologies such as nanoparticles for use in immunological detection, polymer compounds, surfactants, biofuels, photocathode electron sources, and ionic nanocrystalline materials.
Co-author. Modeling pancreatic cancer in vivo. Pancreas. 2010 Apr; 39(3):283-92.
J.D. Cravero, et al. Increased expression of the Akt/PKB inhibitor TRB3 in Osteoarthritic Chondrocytes inhibits IGF-1 mediated cell survival and proteoglycan synthesis. Arthritis & Rheumatism. 2009 Feb; 60(2): 492-500.
Co-author. IGF-I stimulation of proteoglycan synthesis by chondrocytes requires activation of the PI 3-kinase pathway but not ERK MAPK. Biochem Journal. 2005 Aug 1; 389(Pt 3):723-9.